Explore Business Standard
Associate Sponsors
Co-sponsor
Pharma Sctors
The Indian Pharmacopoeia Commission (IPC) has signed memoranda of understanding with the Goa State Pharmacy Council, Quality Council of India, and HLL Infra Tech Services Limited, to strengthen drug safety, quality assurance, and capacity-building initiatives. The IPC, an autonomous body under the Health Ministry, has been making efforts to foster institutional partnerships with regulatory bodies, professional councils, quality organisations, and public sector enterprises to strengthen pharmacovigilance systems, enhance professional competencies, and promote uniform standards for medicine quality and patient safety across India. The memorandum of understanding (MoU) signed between IPC and Goa State Pharmacy Council (GSPC) provides a structured framework for collaboration in pharmacovigilance, rational use of medicines, and professional development of pharmacists in the state, the health ministry said in a statement. It envisages promotion of the National Formulary of India among ...
India Inc can draw inspiration from the domestic pharma industry, which transformed itself in the aftermath of the TRIPS Agreement in 1995, to deal with an unpredictable global tariff regime, according to the Economic Survey 2025-26. The pharmaceutical sector, which had expanded under the process-patent regime of the 1970 Patent Act, faced a sudden change in its operating environment when the TRIPS-compliant product-patent regime took effect in 1995. This shift challenged the very foundation of India's competitive advantage, reverse engineering, and cost-efficient process innovation. However, the manner in which the sector responded offers a compelling template for industries currently confronting rising external trade barriers, especially tariff escalations in major markets, the Economic Survey stated. The new regime enabled Indian firms to legally replicate patented drugs by developing alternative production pathways, thereby creating one of the most affordable pharmaceutical ...
Brazil and Nigeria are emerging as key export destinations for Indian pharmaceutical firms amid global economic uncertainties, according to the commerce ministry data. Nigeria emerged as one of the fastest growing destinations, adding USD 179 million in exports and contributing over 14 per cent to the total export growth during the first eight months of this fiscal year. During April-November FY26, Brazil also recorded an increase of nearly USD 100 million exports, the data showed. "These markets reflect rising healthcare access, expanding public procurement, and growing reliance on Indian generics, reinforcing India's role as a preferred supplier to high growth demand intensive regions," an official said. The country's pharmaceutical exports rose by 6.5 per cent to USD 20.48 billion during April-November 2025-26. The data also showed that the US continues to be the single largest destination, accounting for over 31 per cent of exports in April-November 2025, while the overall gro
The Supreme Court on Tuesday said procedures under the uniform code for pharmaceutical marketing should be so strong that any consumer who is cheated should have access and proper remedy against unethical practices. A bench of justices Vikram Nath and Sandeep Mehta observed there should be appropriate measures where the consumers have a convenient mechanism for lodging their complaints and ensuring that action is taken against erring companies. The top court was hearing a plea seeking that the uniform code of pharmaceutical marketing practices should curb alleged unethical practices of pharma firms. Additional Solicitor General K M Nataraj, appearing for the Centre, said the government has introduced several policies for the purpose of either restricting the pricing of medicines and to regulate such activities. He referred to the Uniform Code for Pharmaceuticals Marketing Practices (UCPMP), 2024, which prohibits pharma companies from offering gifts and travel facilities to healthca